Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
| 24050 | |
| 24450 | |
| - | |
| 24950 | |
| 23950 | |
| 18000-45850 | |
| 934 652 M | |
| 28 102 K | |
| 4 848 M | |
| 441.9885 | |
| 0.7722 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ...
With the efficacy comparable to rival drugs, Oscotec plans to advance to the next step, leaving the door open for partnership PANGYO, South Korea, Feb. 24, 2023 /PRNewswire/ -- Oscotec Inc. announced...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
